Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.34 |
| ▸ | SIK1 | P57059 | 1/20 | 0.32 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24823464 | 0.86 | NLRP3 (0.33) | CYP11B1CYP11B2NLRP3SIK1SIK3 | |
| SCHEMBL24824803 | 0.79 | TLR8 (0.38) | CYP11B1CYP11B2HCRTR1HCRTR2 | |
| SCHEMBL24822783 | 0.77 | PIK3CA (0.31) | CYP11B1CYP11B2 | |
| SCHEMBL24823461 | 0.74 | CYP11B1 (0.34) | CYP11B1CYP11B2 | |
| SCHEMBL24823462 | 0.73 | MAOA (0.33) | NLRP3HCRTR1 | |
| SCHEMBL24497543 | 0.72 | CYP11B1 (0.37) | CYP11B1CYP11B2NLRP3SIK1SIK3 | |
| SCHEMBL27172210 | 0.71 | CYP11B1 (0.33) | CYP11B1CYP11B2 | |
| SCHEMBL29992134 | 0.71 | CYP11B1 (0.33) | CYP11B1CYP11B2 | |
| SCHEMBL24497511 | 0.71 | ALOX5AP (0.38) | CYP11B1CYP11B2 | |
| SCHEMBL24824796 | 0.70 | PIK3CA (0.33) | CYP11B2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411384-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2022-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411384-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | TYK2, JAK2, STAT3 | CYP11B1 573/4885CYP11B2 321/4885NLRP3 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.